Table 1 Clinical characteristics of NPC patients with N3 disease
Characteristic | Chemoradiotherapy-non-MC Patients (n = 109) | Chemoradiotherapy-MC Patients (n = 21) | p value |
|---|---|---|---|
Gender, n (%) | 0.101 | ||
Male | 68 (62.4) | 17 (81) | |
Female | 41 (37.6) | 4 (19) | |
Age, y | 0.989 | ||
Median | 46 | 42 | |
Range | 18–65 | 26–65 | |
Pathology (World Health Organization) | 0.960 | ||
Type II | 10 (9.2) | 2 (9.5) | |
Type III | 99 (90.8) | 19 (90.5) | |
Dose (Gy, range) | 0.961 | ||
GTV | 69.96 | 69.75 | |
Range | 69.3–74.2 | 69.7–70.95 | |
T stage, n (%) | 0.074 | ||
T1 | 12 (11) | 7 (33.3) | |
T2 | 28 (25.7) | 6 (28.6) | |
T3 | 36 (33) | 4 (19) | |
T4 | 33 (30.3) | 4 (19) | |
NeoCT (cycles), n (%) | |||
2 | 31 (28.4) | 0 | 0.002 |
3 | 65 (59.6) | 15 (71.4) | |
4 | 10 (9.2) | 3 (14.3) | |
6 | 3 (2.8) | 3 (14.3) | |
ConCT (cycles), n (%) | 0.202 | ||
0 | 19 (17.4) | 5 (23.8) | |
1 | 21 (19.3) | 2 (9.5) | |
2 | 61 (56) | 14 (66.7) | |
3 | 8 (7.3) | 0 | |
AdjCT (cycles), n (%) | 0.076 | ||
0 | 59 (54.1) | 18 (85.7) | |
1 | 35 (32.1) | 2 (9.5) | |
2 | 13 (11.9) | 1 (4.8) | |
3 | 2 (1.8) | 0 | |
Total chemotherpy (cycles)a, n (%) | 0.889 | ||
Median | 5 | 5 | |
Range | 2–7 | 3–8 | |
Response to NeoCT | 0.120 | ||
CR | 1 (0.9) | 2 (9.5) | |
PR | 105 (96.3) | 18 (87.7) | |
SD | 3 (2.8) | 1 (4.8) | |
Short-term treatment responseb | 0.584 | ||
CR | 59 (54.1) | 10 (47.6) | |
PR | 50 (45.9) | 11 (52.4) | |